Announced Tue, 2 Jun · 16:01 IST

Goldline Pharmaceutical Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/06/2026 ,inter alia, to consider and approve Standalone Audited ....

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-0.2%1-day move
₹44.10
prior close
₹44.97
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-5.5-5.5-3.3-3.3-0.2+2.6+0.2-1.0+8.8+5.4+1.8-4.5
Up moveDown movePending
AI summary

Goldline Pharmaceutical Ltd has informed BSE that its Board of Directors will meet on Tuesday, June 9, 2026 at the registered office in Nagpur. The main agenda is to consider and approve the Standalone Audited Financial Results for the half-year and full year ended March 31, 2026, along with the Statement of Assets and Liabilities. This is a routine advance intimation filed under SEBI Listing Regulations. The actual financial results will be disclosed separately after the meeting concludes. No financial numbers or outcomes have been shared in this filing.

Likely market impact

No immediate impact on shareholders or stock price as this is merely a notice of an upcoming board meeting. Investors should watch for the actual results announcement on or after June 9, 2026 for any meaningful financial updates.